WuXi MedImmune Biopharmaceutical Co. Ltd.

To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose and multiple-ascending doses of WBP216 in RA patients.

To evaluate the PK and PD characteristics of multiple administrations of different doses of WBP216 in patients with rheumatoid arthritis (RA), and to assess the safety and tolerability after multiple administrations, to preliminarily explore the effectiveness of WBP216 in RA patients, and to provide a scientific basis for determining the dosing regimen (including dosage and dosing cycle) for subsequent Phase II and III clinical trials.